Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and neurodegenerative disorders, today announced that the board of directors of the Company approved a 1-for-75 reverse stock split (the "Reverse Split") of the Company’s common stock. The Reverse Split was approved by the stockholders at the Company’s annual meeting of the stockholders held on July 22, 2026. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on August 6, 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.